Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.94
- Piotroski Score 3.00
- Grade Buy
- Symbol (ANAB)
- Company AnaptysBio, Inc.
- Price $21.16
- Changes Percentage (4.16%)
- Change $0.85
- Day Low $20.23
- Day High $21.63
- Year High $41.31
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $45.00
- High Stock Price Target $90.00
- Low Stock Price Target $30.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$6.14
- Trailing P/E Ratio -3.82
- Forward P/E Ratio -3.82
- P/E Growth -3.82
- Net Income $-163,619,000
Income Statement
Quarterly
Annual
Latest News of ANAB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Moderna and Mitsubishi Tanabe link on mRNA vaccines in Japan
Moderna and Mitsubishi Tanabe Pharma have partnered to promote Moderna's mRNA respiratory vaccine portfolio in Japan, including the Covid-19 vaccine, Spikevax. The collaboration aims to enhance public...
By Yahoo! Finance | 4 months ago -
BOJ must avoid raising rates to combat weak yen, says ex-c.banker Watanabe
By Leika Kihara and Takahiko WadaTOKYO (Reuters) - The Bank of Japan must avoid raising interest rates to combat a weak yen, as higher borrowing costs would hit consumption and services inflation,...
By Reuters | 6 months ago -
Japan won't intervene unless yen slides below 155, says ex-FX diplomat Watanabe
By Leika Kihara and Yoshifumi TakemotoTOKYO (Reuters) - Japanese authorities likely won't intervene in the currency market unless the yen plunges below 155 to the dollar, former top currency diplo...
By Reuters | 7 months ago
